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The dopamine D2 receptor (D2R) is known to elicit effects through activating two major
signaling pathways mediated by either G proteins (Gi/o) or β-arrestins. However, the
specific role of each pathway in physiological or therapeutic activities is not known with
certainty. One approach to the dissection of these pathways is through the use of drugs
that can selectively modulate one pathway vs. the other through a mechanism known
as functional selectivity or biased signaling. Our laboratory has previously described a
G protein signaling-biased agonist, MLS1547, for the D2R using a variety of in vitro
functional assays. To further evaluate the biased signaling activity of this compound, we
investigated its ability to promote D2R internalization, a process known to be mediated
by β-arrestin. Using multiple cellular systems and techniques, we found that MLS1547
promotes little D2R internalization, which is consistent with its inability to recruit β-arrestin.
Importantly, we validated these results in primary striatal neurons where the D2R is most
highly expressed suggesting that MLS1547 will exhibit biased signaling activity in vivo.
In an effort to optimize and further explore structure-activity relationships (SAR) for this
scaffold, we conducted an iterative chemistry campaign to synthesize and characterize
novel analogs of MLS1547. The resulting analysis confirmed previously described SAR
requirements for G protein-biased agonist activity and, importantly, elucidated new
structural features that are critical for agonist efficacy and signaling bias of the MLS1547
scaffold. One of the most important determinants for G protein-biased signaling is the
interaction of a hydrophobic moiety of the compound with a defined pocket formed
by residues within transmembrane five and extracellular loop two of the D2R. These
results shed new light on the mechanism of biased signaling of the D2R and may lead
to improved functionally-selective molecules.
Keywords: D2 dopamine receptor, functional selectivity, biased signaling, structure-activity relationship,
MLS1547, quinoline
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INTRODUCTION
The D2 dopamine receptor (D2R) is one of the most validated
drug targets in the treatment of psychiatric and neurological
diseases. Unfortunately, many of the drugs that target the D2R
exhibit adverse side effects, which can be both on and off target
in nature. The D2R stimulates both G protein- and β-arrestin-
mediated pathways to elicit a variety of downstream signaling
effects (Beaulieu and Gainetdinov, 2011). Activation of Gi/o
proteins inhibits adenylyl cyclase-mediated cAMP production
(Sibley and Monsma, 1992; Missale et al., 1998) whereas
activated Gβγ subunits inhibit L/N-type calcium channels (Yan
et al., 1997; Hernandez-Lopez et al., 2000) and activate G
protein-coupled inward rectifying potassium (GIRK) channels
(Kuzhikandathil et al., 1998; Lavine et al., 2002; Luscher and
Slesinger, 2010). D2R activation also triggers the recruitment
of β-arrestin-2 (also referred to as arrestin-3) to the receptor
resulting in D2R internalization (Skinbjerg et al., 2009) and
activation of β-arrestin-mediated signaling cascades leading to
glycogen synthase kinase-3 (GSK3) activation and downstream
signaling (Beaulieu et al., 2007, 2015). This complicated milieu
of dopamine-mediated signaling makes it difficult to discern
which of these pathways are important for D2R-related pathology
and/or treatment goals. Dissection of these pathways is thus a
primary objective in understanding the physiological effects of
D2R signaling while the selective targeting of specific pathways
may enhance the therapeutic efficacy and side-effect profiles of
D2R-related drugs.
Most agonists, in particular the endogenous transmitter, will
activate all signaling pathways of a particular receptor with
equal or similar efficacies. However, it is now recognized that
some agonists may preferentially activate one signaling pathway
vs. another or even activate one while inhibiting another. This
phenomenon, referred to as functional selectivity or biased
signaling has been observed for many different GPCRs and found
to encompass not only different signaling pathways, but also
other agonist-induced responses such as desensitization/down-
regulation (Galandrin et al., 2007; Kenakin, 2007; Leach et al.,
2007; Mailman, 2007; Urban et al., 2007; Violin and Lefkowitz,
2007; Evans et al., 2011). While the mechanisms underlying
biased signaling are not known with certainty, a leading
hypothesis is that GPCRs can adopt multiple functionally active
conformational states that are stabilized or induced by selective
ligands (Kobilka and Deupi, 2007; Wess et al., 2008; Bokoch
et al., 2010). Structural data supporting hypotheses for biased
activation of GPCRs have recently been described (Liu et al.,
2012; Rahmeh et al., 2012; Wacker et al., 2013), suggesting that
the rational design of functionally-selective or signaling-biased
compounds may be achievable.
Like many GPCRs, the D2R can exhibit biased signaling
in response to agonists that are functionally selective (Lawler
et al., 1999; Mailman, 2007) including those that are biased for
stimulating either G protein- (Free et al., 2014; Moller et al., 2014,
2017; Weichert et al., 2015; Chen et al., 2016; Bonifazi et al.,
2017) or β-arrestin-mediated signaling (Allen et al., 2011; Chen
Abbreviations: SAR, structure-activity relationship.
et al., 2012; Hiller et al., 2013; Weichert et al., 2015; Mannel
et al., 2017a,b). The growing availability of these pharmacological
tools is expected to greatly assist in determining the physiological
roles and therapeutic significance of D2R-stimulated G protein
and β-arrestin-mediated signaling. Using a variety of in vitro
functional assays, we previously described one such G protein-
biased D2R agonist, MLS1547, which was found to be highly
efficacious for G protein-mediated signaling (inhibition of cAMP
production), but relatively ineffective for recruiting β-arrestin
(Free et al., 2014). Over two dozenMLS1547 analogs with varying
degrees of signaling bias were further characterized and used
to computationally develop a pharmacophore model to explain
the biased signaling properties of this chemical scaffold. In brief,
it was postulated that the scaffold must contain a hydrophobic
binding moiety, two aromatic groups, and a positively charged
nitrogen all in the correct orientation (Free et al., 2014). Further,
molecular dynamics simulations using an active state model of
the D2R suggested a binding pose where biased, but not unbiased,
ligands interact with a hydrophobic pocket formed by residues
near the extracellular end of the 5th transmembrane domain
(TM5) of the receptor (Free et al., 2014). These interactions have
been hypothesized to affect the tilting of TM5, which might bias
the D2R to preferentially activating G proteins vs. recruiting
β-arrestin (Free et al., 2014).
In the current study, we sought to further characterize the
biased signaling properties of the MLS1547 scaffold through
examining its ability to modulate D2R internalization, which is
mediated by β-arrestin-2 (Skinbjerg et al., 2009). Importantly,
these assays were extended to primary neuronal cell model
systems, which more likely replicate the cellular milieu in which
the D2R normally propagates intracellular signals. Interestingly,
the biased signaling properties of MLS1547 that were observed
in heterologous expression systems were largely replicated in the
neuronal model systems. We also sought to further elucidate
the structure-activity relationships (SAR) for the biased signaling
properties of MLS1547 through the synthesis and evaluation of
50 MLS1547 analogs. These compounds were examined in both
G protein- and β-arrestin-mediated signaling assays and were
found to exhibit a wide range of D2R agonist activities. These
analyses confirmed previously described SAR requirements for
G protein-biased agonist activity and, importantly, elucidated
new structural features that are critical for agonist activity




MLS1547 was originally obtained from the NIH Molecular
Libraries Screening Center Network Library and subsequently
purchased from MolPort (Riga, Latvija) for follow-up triage
studies. Subsequent batches of the compound, along with all
analogs, were synthesized at the University of Kansas Specialized
Chemistry Center. All compounds were evaluated via NMR to
confirm purity (>90%) and structural veracity. Identical results
were obtained with all batches from all sources. All other
chemicals were obtained from Sigma-Aldrich (St. Louis, MO)
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unless otherwise indicated. All tissue culture media and materials
were obtained from Corning/Mediatech, Inc. (Manassas, VA).
cAMP Inhibition Assay
Assays were performed as previously described (Free et al.,
2014). Briefly, D2R-mediated inhibition of forskolin-stimulated
cAMP production was assayed using the DiscoverX HitHunter
assay kit (DiscoverX, Inc., Fremont, CA). CHO-K1 cells stably
expressing the human D2R long isoform were purchased from
DiscoverX, Inc. and maintained in Ham’s F12 supplemented
with 10% fetal bovine serum, 100 U/ml penicillin, 100µg/ml
streptomycin, 20mM HEPES, and 800µg/ml G418 at 37◦C, 5%
CO2, and 90% humidity. Cells were seeded in Cell Plating Media
2 (DiscoverX, Inc.) at a density of 5,000 cells/well in 384-well
black, clear-bottom plates. After 16–24 h, medium was removed
and replaced with 5 µl/well phosphate-buffered saline (PBS).
Compounds were diluted in PBS in the presence of 100µM
forskolin and 0.2µM sodium metabisulfite. Cells were treated
with 2.5µl of various concentrations of compound and incubated
for 60min at 37◦C. ED, lysis buffer, cAMP antibody, and emerald
II reagents were added as directed by the manufacturer and cells
were incubated for 1 h at room temperature. EA reagent was
added to the plates and luminescence (RLU) was measured using
an FDSS µCell (Hamamatsu Photonics K.K., Bridgewater, NJ)
following a 3 h incubation in the dark at room temperature. Data
were collected as relative luminescence units (RLUs), and values
were normalized to a percentage of the control luminescence seen
with a maximum concentration of dopamine for agonist mode
assays. The Hill coefficients of the concentration-response curves
did not significantly differ from unity with the data fitting to a
single site model.
β-Arrestin Recruitment Assay
Assays were conducted with minor modifications as previously
published by our laboratory (Banala et al., 2011; Bergman et al.,
2013; Free et al., 2014; Meade et al., 2015), using the DiscoverX
PathHunter technology (DiscoverX, Inc., Fremont, CA). Briefly,
CHO-K1 cells expressing the D2R long isoform (DiscoverX, Inc.)
were maintained in Ham’s F12 media supplemented with 10%
fetal bovine serum, 100 U/ml penicillin, 100µg/ml streptomycin,
20mMHEPES, and 800µg/ml G418 and 300µg/ml hygromycin
at 37◦C, 5% CO2, and 90% humidity. For assay, the cells
were seeded in Cell Plating Media 2 (DiscoverX, Inc.) at a
density of 2,625 cells/well in 384-well black, clear-bottom plates.
Compounds were diluted in PBS in the presence of 0.2µM
sodiummetabisulfite. Following 24 h of incubation, the cells were
treated withmultiple concentrations of compound and incubated
at 37◦C for 90min. DiscoverX reagent was then added to cells
according to the manufacturer’s recommendations followed by
a 45min incubation at room temperature. Luminescence was
measured on a Hamamatsu FDSS µCell reader. Data were
collected as RLUs and subsequently normalized to a percentage
of the control luminescence seen with a maximum concentration
of dopamine for agonist mode assays. The Hill coefficients of the
concentration-response curves did not significantly differ from
unity.
Primary Glia and Striatal Neuron Culture
Isolation and culturing of cells was conducted as described
previously (Li et al., 2012b; Daly et al., 2015) using C57BL6/J
mice. All experiments using laboratory animals were conducted
with approved protocols from the NIH/NIDA Animal Care and
Use Committee.
Glia Cultures
Dissection buffer consisting of ACSF: 119mM NaCl, 5mM KCl,
1mM MgCl2, 30mM dextrose, 25mM HEPES, pH 7.4, without
calcium) and glia media (DMEM supplemented with 10% FBS,
10 U/ml penicillin, 10µg/ml streptomycin, and Glutamax) were
prepared and stored at 4◦C until ready for use. Embryonic or
neonatal C57BL6/J mice were euthanized by rapid decapitation.
Cerebral cortices were dissected and placed into 15ml concial
tubes with 5–10ml of ice-cold dissection buffer. Tissue was then
digested in 2ml of papain solution [100 µl papain, 20 mg/ml
slurry (Worthington Biochemical Corp.), 20 µl of 1% DNase
I (Sigma, cat. no. DN25-10MG), and 2ml dissection buffer]
for 20min at 37◦C. Following digestion, tissue was rinsed with
10ml pre-warmed glia media, triturated with a fire-polished glass
Pasteur pipette, diluted in glia media and filtered through a
70µm cell-strainer. Cells were then seeded into collagen coated
T75 flasks (2–3 embryos/flask) and placed into a 37◦C cell culture
incubator overnight with media replacement the next day. Cells
were dissociated with 0.05% trypsin when nearing confluence
in 10–12 days. Glia were cultured directly onto collagen coated
inserts (Millipore PICM03050) placed in six-well plates (one
confluent T75 flask per 6-well plate/2 ml/insert) and used for
conditioning neuronal cultures.
Neuronal Cultures
Pregnant C57BL6/J mice (E15-18) were euthanized with CO2,
and embryonic mice were euthanized by decapitation. Striata
were dissected from the brain and placed into a 15ml conical
tube with ice-cold dissection buffer. Tissues were dissociated
with papain as described above and the resulting cells quantified.
Neurons were then seeded onto poly-L-lysine coated glass
coverslips in plating media: Neurobasal media (ThermoFisher,
Inc.) supplemented with 5% heat-inactivated horse serum, 10
units/ml penicillin, 10µg/ml streptomycin, Glutamax; 2% B27
supplement at a density of 0.4× 106 cells/well of a six-well plate,
and cultured in a 37◦C incubator overnight (neurons are DIV 0).
The next day (DIV 1), coverslips containing neurons were placed
underneath the glia culture inserts, one coverslip/well.
Primary striatal neurons were transfected 7–8 days after
culturing with 1 µg of D2R-pHluorin DNA construct (Li et al.,
2012a) using 2 µl of Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) according to the manufacturer’s recommendations for each
neuronal culture/coverslip. Briefly, Lipofectamine 2000 reagent
and DNA construct were diluted in supplement-free Neurobasal
medium and incubated for 20min at room temperature. Glia
culture inserts were removed momentarily from the six-well
plates and 200 µl Lipofectamine/DNA mixture was added to
each coverslip, followed by return of the glia culture inserts to
each well. Neurons were incubated with the Lipofectamine/DNA
mixture at 37◦C for 2–4 h. After the 2–4 h incubation period,
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glia inserts were removed again and the media containing the
Lipofectamine/DNA mixture was removed, Glia culture inserts
were returned to each well, and the glia media from each insert
was changed. Neurons were cultured for an additional 24–72 h
prior to imaging.
D2R Immunocytochemistry
Striatal neurons were transfected with pH-DRD2 for 48 h as
previously described (Li et al., 2012a), washed with ACSF, and
incubated with rabbit polyclonal anti-GFP antibody (1:200
dilution; a gift from Dr. Richard L. Huganir, Department
of Neuroscience, Johns Hopkins University School of
Medicine/HHMI) for 1 h at 4◦C to stain surface receptors.
Neurons were subsequently fixed with Parafix (4% sucrose,
4% paraformaldehyde in PBS, pH 7.4), permeabilized with
0.25% Triton X-100 in PBS, blocked with 10% normal donkey
serum in PBS at 37◦C for 1 h, and subsequently stained with a
mouse monoclonal GFP antibody at a dilution of 1:100 (a gift
from Dr. Richard L. Huganir) to stain for total pH-DRD2 to
amplify green fluorescent signal from superecliptic pHluorin
at neutral pH. Neurons were then washed four times and
subsequently stained with Alexa Fluor 647 Red-X donkey
anti-Rabbit IgG (H+L; 1:100 dilution; catalog# 647 711-605-152,
Jackson Immunoresearch Laboratories, Inc.) and Alexa Fluor
488 donkey anti-mouse IgG (H+L; 1:200 dilution; catalog#
705-545-147, Jackson Immunoresearch Laboratories, Inc.)
secondary antibodies. Images were acquired on an inverted
Zeiss fluorescent microscope using a 40X objective (NA, 1.30)
and a 2.5X relay lens between the microscope and the camera.
Fluorescent intensities were quantified using ImageJ (NIH,
https://imagej.nih.gov/ij/). The ratio between surface/total of
pH-DRD2 signal was normalized to the control group (pH-
DRD2 without DA stimulation) as 100%. Compounds were
diluted in PBS in the presence of 0.2µM sodium metabisulfite.
Total Internal Reflection Fluorescence
Microscopy (TIRFM)
TIRF imaging was conducted on a custommade in-house system
with a 100-mW Cyan laser for excitation, and an Electron
Multiplying Charge Coupled Device (EMCCD) camera for a
detector. Prior to imaging experiments, a coverslip containing
transfected neurons as described above is assembled into a
live-imaging chamber and incubated with ACSF. Transfected
neurons are identified visually under epifluorescent imaging,
and subject to a 1min photo-bleach to eliminate pre-existing
pHluorin fluorescence on the plasma membrane. Following
photobleaching, recording is performed for 1min at 10Hz with
each recording containing 600 images and the gain setting of
the electron multiplier set to maximum. Individual insertion
events are identified in the recording ImageJ, and analyzed
manually.
Biotinylated D2R Internalization Assay
Experiments were performed as previously described (Lee et al.,
2007). Briefly, HEK293 cells transfected with HA-D2R were
washed with cold PBS (137mM NaCl, 2.7mM KCl, 10mM
Na2HPO4, 2mM KH2PO4) and incubated in 0.5 mg/ml Sulfo-
NHS-SS-biotin (Pierce/Thermo Fisher, Inc.) in PBS at 4◦C for
30min. Cells were washed with PBS to remove and quench
residual biotinylation reagent and then placed in culture medium
for 30min with either vehicle (control), quinpirole, or MLS1547
(dissolved in buffer plus 0.1%DMSO). Cells were then washed on
ice with PBS, and the remaining cell surface biotinylated proteins
were stripped twice for 15min each using 100mM MESNA
(Sigma-Aldrich, Inc.) dissolved in solution containing 50mM
Tris pH 8.8, 100mMNaCl, 1mM EDTA, and 0.2% BSA. Stripped
cells were then quenched with iodoacetamide buffer (22 mg/ml
iodoacetamide in PBS) for 10min at 4◦C. Cells were extracted
with lysis buffer [0.5% sodium deoxycholate (DOC), 1% NP40,
150mM NaCl, 10mM Tris pH 7.4, 1% Triton X-100, 0.1% SDS]
supplemented with protease inhibitor cocktail (Sigma-Aldrich,
Inc.). Cell debris was removed by centrifugation at 13,000 g for
15min at 4◦C. Extracts containing equal amounts of cellular
protein (determined using BCA protein assay) were incubated
with immobilized streptavidin beads on a rotator overnight
at 4◦C. Protein-bound streptavidin beads were centrifuged at
3,000 g for 1min at 4◦C and washed three times with lysis
buffer. Proteins were eluted and denatured in SDS sample
buffer and separated by SDS-PAGE. Proteins were transferred
to nitrocellulose and biotinylated proteins were detected by
immunoblotting with anti-HA (for D2R) (Roche, Inc.) and
anti-TfR (for transferrin receptor) (Santa Cruz Biotechnology,
Inc.).
BRET Biosensor-Based D2R Internalization
Assay
BRET assays for measuring receptor internalization were
performed by tagging plasma membrane (PM) anchored Lyn-
kinase’s acylation moiety with GFP10 (lyn-GFP10) and were
performed as described previously (Namkung et al., 2016).
Briefly, HEK293SL cells were cultured in DMEM supplemented
with 5% fetal bovine serum and 20µg/ml gentamycin and
maintained at 37◦C in 5% CO2 and 90% humidity. Cells were
seeded at ∼7.5 × 105 cells per 100mm dishes and transfected
with D2S-RLuc8 and lyn-GFP10 the following day using calcium
phosphate (Simaan et al., 2005). After 18 h of transfection,
the medium was replaced, and the cells were replated onto
poly-ornithine coated white 96-well plates (∼25,000 cells/well).
The next day, cells were washed once with pre-warmed
Tyrode’s buffer (140mM NaCl, 2.7mM KCl, 1mM CaCl2,
12mM NaHCO3, 5.6mM D-glucose, 0.5mM MgCl2, 0.37mM
NaH2PO4, 25mM HEPES, pH 7.4), and then stimulated with
various concentrations of ligands in Tyrode’s buffer in the
presence of 0.2mM sodium metabisulfite for 30min at 37◦C.
The cell-permeable substrate, coelenterazine 400a was added
at a final concentration of 5µM in Tyrode’s buffer 3–4min
before BRET measurements. Measurements were performed by
using Synergy2 (BioTek R©) microplate reader with a filter set of
410/80 and 515/30 nm for detecting the Rluc8 renilla luciferase
(donor) and GFP10 (acceptor) light emissions, respectively.
The BRET signal was determined by calculating the ratio
of the light intensity emitted by the GFP10 over the light
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intensity emitted by the Rluc8. Experiments were performed in
triplicate and the data expressed as mean ± SEM of the BRET
ratio.
Chemistry





MLS1547 has previously been characterized as a G protein-
biased agonist at the D2R, displaying high efficacy in stimulating
G protein-mediated signaling, but no observable efficacy in
recruiting β-arrestin-2, as detected using several cell-based assays
(Free et al., 2014). As agonist-induced D2R internalization has
been shown to be mediated by β-arrestin-2 (also referred to as
arrestin-3) (Skinbjerg et al., 2009), we sought to evaluate the
effects of MLS1547 on D2R internalization using several different
methods.
In a first approach, we used a BRET-based biosensor that
employs a modified GFP protein, which is cell surface-localized
(Namkung et al., 2016) and see Methods. Co-transfection of
D2R-Rluc8 and the cell surface-localized GFP-tagged protein in
HEK293 cells results in constitutive BRET when they are both
expressed at the cell surface and in close proximity. Upon agonist
stimulation, the receptor is internalized but the GFP-tagged
protein remains in the plasma membrane resulting in a decrease
in the BRET ratio due to separation of the BRET donor (D2R-
Rluc8) and acceptor (GFP) (Namkung et al., 2016). As shown
in Figure 1A, stimulation with DA resulted in a dose-dependent
decrease in the BRET ratio. When the cells were stimulated with
MLS1547, they failed to elicit a significant change in BRET ratio
at a concentration up to 30µM, which results in full activation
of G protein signaling (Free et al., 2014 and see below) and
fully occupies the D2R as shown using radioligand binding
assays (Free et al., 2014). Figure 1B shows single concentration
data using 10µM of DA or 30µM of MLS1547. DA treatment
promoted significant receptor internalization, whereas MLS1547
treatment did not significantly change the BRET signal. These
initial findings suggest that MLS1547 is relatively ineffective in
D2R internalization when compared to DA.
We next took a different approach to assess agonist-induced
internalization using a cell surface biotinylation assay and
transient expression of an HA-tagged D2R in HEK293 cells.
In this method, the D2R is labeled with biotin at the cell
surface followed by agonist treatment of the cells. Biotin is then
cleaved from cell surface proteins (internalized receptors are
protected from cleavage) followed by lysis and isolation of the
biotinylated proteins via binding to avidin beads (Lee et al., 2007).
Figure 1C shows a Western blot of internalized D2R protein
after treatment with 10µM of MLS1547 or 10µM of the D2R
agonist quinpirole. The D2R is visualized using an antibody
directed to an HA tag on the receptor (top blot). Visualization
of the transferrin receptor (TfR) was also performed as a gel
loading control (bottom blot). The blots were quantified using
densitometric analyses and graphed as a percentage of D2R
protein divided by the loading control (TfR), with untreated
control levels being set to 1.0 (Figure 1D). Notably, treatment
with the D2R agonist quinpirole resulted in a robust loss
of cell surface D2R protein (Figure 1D). MLS1547 treatment
also resulted in statistically significant receptor internalization,
however, this response was only a fraction of that produced by
quinpirole (Figure 1D). Thus, these results differed somewhat
from those obtained using the BRET assay (Figures 1A,B) in that
MLS1547 promoted a small, but detectable amount of receptor
internalization.
As the above experiments used non-neuronal cells (HEK293)
to examine D2R internalization, we wished to examine this
response within a neuronal context. Thus, we performed studies
to examine D2R internalization and recycling in striatal neurons
from E15-E18 mouse embryos using both immunocytochemistry
(ICC) and total internal refection fluorescent (TIRF) microscopy
(Li et al., 2012a,b; Daly et al., 2015). Figure 2A shows
quantification of ICC assays following treatment of the
transfected cells with either 10µMDA, 30µMMLS1547, 30µM
of the D2R antagonist sulpiride, or vehicle (control). Data are
expressed as the ratio of surface to total receptors normalized
to the control. Notably, DA treatment resulted in a significant
decrease in D2R surface expression when compared to the
control. Interestingly, MLS1547 promoted a low, but statistically
significant, degree of receptor internalization when compared
to the control, however, this response was much less than that
observed with DA. The D2R antagonist sulpiride was used
as a negative control and, as expected, no significant D2R
internalization was detected after sulpiride treatment.
For TIRF microscopy studies, the neurons were transfected
with a D2R construct tagged with a pH-dependent GFP
(pHluorin) that loses fluorescence in the acidic environment of
internalized vesicles (Li et al., 2012a,b; Daly et al., 2015). This
enables the visualization of vesicle exocytosis or “reinsertion,”
as pHluorin fluorescence is regained the moment the vesicle
fuses with the cell membrane. It has been shown that increased
receptor internalization correlates to an increase in reinsertion
frequency, which is theorized to be due to recycling of D2Rs back
to the cell membrane following agonist-stimulated endocytosis
(Li et al., 2012a,b). The frequency of D2R-containing vesicle
reinsertion was measured via real-time TIRF microscopy by
photobleaching the neurons and then treating them for 20min
with either 10µM DA, 30µM MLS1547, 30µM sulpiride, or
vehicle (control) (Figure 2B). DA treatment caused a significant
increase in reinsertion frequency when compared to the control
correlating to an increase in receptor internalization. In contrast,
MLS1547 treatment did not result in a significant increase in
reinsertion frequency when compared to control. As observed
with the ICC experiments, sulpiride had no effect on D2R
internalization. Taken together, these data show that MLS1547 is
relatively ineffective in promoting D2R internalization in striatal
neurons.
Structural Analogs of MLS1547
In order to better understand the SAR for the biased signaling of
MLS1547, as well as to develop a more optimized compound, an
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FIGURE 1 | Investigation of D2R internalization in non-neuronal cell systems. (A) HEK293 cells were transiently transfected with D2R-Rluc8 and a modified GFP10,
which together produce constitutive bystander BRET. On the day of assay, the cells were stimulated with either dopamine (DA) or MLS1547 for 30min at 37◦C before
BRET measurement. The data are graphed as mean dose-response curves from three independent experiments. DA exhibited an logEC50 of −7.00 ± 0.36 (EC50,
0.1µM) for BRET reduction/D2R internalization, while MLS1547 treatment failed to alter the BRET signal. (B) Maximum BRET signal obtained after treatment with
vehicle (control, 0.81 ± 0.02), 10µM DA (0.65 ± 0.02), or 30µM MLS1547 (0.79 ± 0.03). All data are expressed as mean ± SEM of the BRET ratio from three
independent experiments. *P < 0.05, unpaired Student’s t-test compared to untreated controls. (C) HA-tagged D2R was transiently transfected into HEK293 cells
and surface D2R was biotinylated as described in Methods. After washing, cells were treated with either vehicle (control), 10µM quinpirole, or 10µM MLS1547 or for
30min at 37◦C. Biotin was cleaved from D2R that remained on the cell surface, followed by cell lysis and isolation of biotinylated (internalized) D2R using avidin beads.
Western blotting was used to detect D2R and also transferrin receptor (TfR) (as a gel loading control). A single experiment, representative of three, is shown (the
original full blot is displayed in the Supplemental Materials). (D) Densitometric analyses were performed and the data expressed as D2R/TfR ratios, relative to the
untreated controls (1.0). Treatment values are provided as mean ± S.E.M: quinpirole = 2.8 ± 0.2 and MLS1547 = 1.5 ± 0.03. One-way ANOVA followed by
Bonferroni’s post-test was performed: *p < 0.05, and **p < 0.01.
iterative chemical synthesis of additional analogs was conducted.
Figure 3A illustrates the parental compound 1 and the previously
developed pharmacophore model highlighting four regions of
the molecule that are believed to be important for G protein
bias. These include a hydrophobic binding moiety, two aromatic
groups, and a positively charged feature (Free et al., 2014).
Keeping this model in mind, Figure 3B shows the four main
areas of the molecule that we selected for derivatization to
further investigate the SAR for this scaffold. The target analogs
2–51 were readily prepared via one of the three synthetic
sequences illustrated in Scheme 1, each advantageous for a range
of structural analogs.
For 8-hydroxyquinoline substrates, a Mannich-type reaction
(Blicke, 1942) was employed to directly combine quinoline
fragment such as 52, formaldehyde and a piperazine fragment
such as 53 with simultaneous incorporation of the methylene
linker. Nonphenolic quinolines required a two-step sequence to
utilize benzylic alcohols such as 54 as coupling partners with
piperazine fragments (e.g., 55) to prepare the final analogs.
Replacement of the quinoline with alternative heterocycles was
achieved via coupling of the piperazine fragment (e.g., 55) with
carboxylic acids such as 56 and subsequent amide reduction.
This third sequence also provided the intermediate carboxamide
compounds (e.g., 14) for evaluation as D2R agonists. The
agonist activities for all of the analogs using both G protein
activation (cAMP inhibition) and β-arrestin recruitment assays
are summarized in Tables 1–3 below.
Structure-Activity Relationships for
MLS1547
We previously postulated that a hydrophobic binding pocket
comprised of D2R residues I184, F189, and V190 is required
for the biased signaling activity of MLS1547 (Free et al.,
2014). The chlorine group (area 1) on ring B of MLS1547
(Figure 3B) was hypothesized to interact with this pocket and
prevent the tilting of TM5 during receptor activation. With
this in mind, our first approach was to further investigate the
influence of this hydrophobic binding moiety on compound
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FIGURE 2 | Investigation of D2R internalization in neuronal cell systems. (A) Striatal neurons were prepared and transfected with the D2R-pHluorin construct
(pH-DRD2) as described in Methods. 48 h later, the neurons were treated with vehicle (control) or 10µM dopamine (DA), 30µM MLS1547, or 30µM sulpiride for
45min. Neurons were washed and then stained with a polyclonal GFP antibody to detect surface D2R followed by fixation, permeabilization and re-staining with a
monoclonal GFP antibody to detect total cellular D2R. The ratios between surface to total pH-DRD2 signal were normalized to the control group in each experiment
and are expressed as mean ± S.E.M of the indicated number of cells (n): control = 1.00 ± 0.02, n = 746; DA = 0.72 ± 0.02, n = 627; MLS1547 = 0.90 ± 0.03,
n = 812, sulpiride = 1.05 ± 0.08, n = 171. One-way ANOVA followed by Bonferroni’s post-test was performed: *p < 0.0001 and **p < 0.0262. (B) Striatal neurons
expressing the D2R-pHluorin construct were exposed to vehicle (control) or 10µM DA, 30µM MLS1547, or 30µM sulpiride for 20min and the number of reinsertion
events/(min×µm2 ) were visualized in real time as described in Methods. The average reinsertion frequencies for the drug treatments were normalized to the control
group in each experiment and are expressed as mean ± S.E.M of the indicated number of cells (n): control = 1.00 ± 0.20, n = 51; DA = 5.70 ± 0.54, n = 49;
MLS1547 = 1.73 ± 0.22, n = 50, sulpiride = 1.56 ± 0.34, n = 15. One-way ANOVA followed by Bonferroni’s post-test was performed, *p < 0.0001.
FIGURE 3 | Structure of MLS1547. (A) Pharmacophore model depicting four
required features for agonist activity and G protein bias. Green represents a
hydrophobic component, orange represents two aromatic components, and
purple represents a positively charged component. (B) The four main areas of
the scaffold that were modified are indicated.
bias by constructing multiple analogs that vary in this region
of the molecule. It can be seen that removing the chlorine
group (Tables 1, 2) resulted in a gain in β-arrestin recruitment
activity (loss of signaling bias), whereas replacing the chlorine
group with a bromine (Tables 1, 3) maintained G protein
bias, but resulted in a modest decrease in agonist potency
(Figure 4). Similar replacement of Cl with H in MLS1547
analogs (Table 1, 7 and 8, or Table 3, 39 and 42) lead to less
or non-biased analogs supporting the need for a hydrophobic
moiety at this position to maintain G protein signaling
bias.
Modification or replacement of the phenol on the chlorine-
substituted quinoline ring resulted in a decrease in potency or
loss of efficacy of the compound (Table 1, 4–6), suggesting an
important interaction between this hydroxyl group and the D2R
(Figure 5). Replacement of the phenol with chlorine or methyl
combined with removal of the Area 1 (Figure 3B) chlorine group
(Table 1, 7 and 8) resulted in less biased analogs with agonist
efficacy in both the G protein and β-arrestin assays (Figure 6).
The reduced steric bulk of these analogs could allow for a change
in binding pose that might compensate for the loss of the phenol
interaction. These data suggest that the hydroxyl group on ring B
(Figure 3B) is a strong driver of both potency and efficacy in this
series of compounds and plays a vital role in driving G protein
bias and activity.
Replacement of the quinoline ring with other bicyclic
aromatic moieties primarily resulted in less biased analogs
(Table 1, 9–11). An interesting exception is the 1-naphthalene
group (Table 1, 12) that was both potent and G protein-
biased. We previously found that a naphthalene group can
provide the necessary hydrophobic feature for G protein bias,
but only if orientated correctly such that it can engage the
hydrophobic pocket in the D2R (Free et al., 2014). For instance,
12 is highly G protein-biased whereas 11 is much less biased
(Table 1, Figure 7). Compounds with substituted indole moieties
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SCHEME 1 | Representative synthetic sequences for SAR analogs 1-51. Reagents and conditions: (a) pyridine, formaldehyde (37 wt% in water), 55% yield; (b) MsCl,
Et3N, CH2Cl2; (c) 55, Et3N, DMF, 56% yield (two steps); (d) 55, HATU, DIEA, DMF, 34% yield; (e) LiAlH4, THF, 42% yield.
in a similar orientation as the naphthalene group of the non-
biased compound 11, (Tables 1, 9 and 10), resulted in less
or non-biased signaling activity (Table 1). Other MLS1547
derivatives (Table 3, 37 and 38) with naphthalene groups in
the two different orientations exhibited a similar phenomenon.
For instance, 38 was G protein-biased whereas 37 actually
appeared to exhibit β-arrestin bias, albeit with low potency.
Similarly, 28 was G protein-biased, whereas 27 lost all activity
(Table 3). In aggregate, these data confirm and strengthen
our previously proposed pharmacophore model for biased G
protein signaling of the MLS1547 scaffold. Specifically, that a
hydrophobic moiety is integral to G protein-biased signaling
activity at the D2R, and this interaction can be provided
either through a halogen group, or a hydrophobic ring in the
correct orientation, that interacts with a hydrophobic pocket on
the D2R.
We next performed a preliminary investigation of the
methylene linker (Area 3, Figure 3B) between the bicyclic
aromatic moieties (rings A and B, Figure 3B) and the piperazine
moiety (ring C, Figure 3B) by exchanging it for a carbonyl group
to create carboxamide derivatives. This was performed within
the context of four of the highest potency compounds, 9, 10, 43,
and 44 (Tables 1, 3). The corresponding carboxamide derivatives
13, 14, 47, and 48 lost all activity in the functional assays
(Tables 1, 3). This likely results from a decrease in the basicity of
the adjacent nitrogen, affecting its ability to become protonated
at physiological pH. As previously noted, a positively charged
nitrogen at this position was described in the pharmacophore
model (Figure 3A), which likely forms critical interactions with a
conserved aspartate residue (Asp3.32) within TM3 of the receptor
(Michino et al., 2015). However, it should be noted that the
introduction of a carbonyl group in the linker also greatly
increases the rigidity the scaffold, which might be deleterious for
its interaction with the D2R.
Based on previously published SAR and the pharmacophore
model, the pyridine moiety of MLS1547 (Figure 3B, area 4)
is believed to confer increased agonist potency, likely through
formation of a hydrogen bond to T412 of the D2R (Free et al.,
2014). To further dissect the influence of the pyridine ring, we
initially replaced it with a cyclohexane group within the context
of both G protein-biased and non-biased scaffolds (Table 2, 24
andTable 3, 49-51). Notably, these analogs lost all agonist activity
at both G protein and β-arrestin-mediated signaling. The agonist
potency and G protein selectivity of MLS1547 was restored
in the analog where the 2-pyridyl was replaced with phenyl
(Table 2, 23). These data confirm the notion (Free et al., 2014)
that the aromaticity of ring D is essential for agonist efficacy.
Notably, all of the compounds with cyclohexane substituents
retained binding affinity for the D2R as evidenced by their ability
to antagonize both G protein and β-arrestin recruitment activities
(data not shown).
To further investigate the role of the pyridine moiety in
MLS1547 activity, we modified the location of the nitrogen atom
within the ring. Moving the nitrogen to either the meta- or
para- positions results in a complete loss of agonist activity (e.g.,
Table 2, 15 and 16, and Table 3, 25–27 and 29–30). One notable
exception is 28 (Table 3), which is a low potency partial agonist
with higher efficacy for G protein signaling. Substitution of the 2-
pyridyl group at the para-position also appears to be detrimental
to potency, as the trifluoromethyl analog (Table 2, 20) lost
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TABLE 1 | Modification and replacement of the hydroxyquinoline group (R1).
Entry/cmpd
Structure (R1 =)
cAMP inhibition assay β-arrestin recruitment assay
EC50 (µM ± SEM) Emax (% DA control ± SEM) EC50 (µM ± SEM) Emax (% DA control ± SEM)
1 (MLS1547) 2.2 ± 0.6 95.4 ± 8.9 NA NA
2 0.3 ± 0.09 97.1 ± 0.9 0.9 ± 0.3 58 ± 8.4
3 7.9 ± 2.1 75.0 ± 3.9 NA NA
4 13.4 ± 11.7 37.9 ± 8.1 NA NA
5 NA NA NA NA
6 NA NA NA NA
7 6.6 ± 5.5 56.8 ± 8.3 7.3 ± 1.8 30.1 ± 1.1
8 1.4 ± 0.7 48.9 ± 5.4 9.3 ± 2.9 22 ± 1.6
9 1.6 ± 1.3 51.9 ± 13.8 9.3 ± 6.1 60.8 ± 6.0
10 0.2 ± 0.1 75.4 ± 7.6 0.7 ± 0.1 60.9 ± 6.4
11 0.1 ± 0.07 93.1 ± 1.6 0.9 ± 0.6 63.3 ± 8.9
(Continued)
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TABLE 1 | Continued
Entry/cmpd
Structure (R1 =)
cAMP inhibition assay β-arrestin recruitment assay
EC50 (µM ± SEM) Emax (% DA control ± SEM) EC50 (µM ± SEM) Emax (% DA control ± SEM)
12 0.7 ± 0.7 89.5 ± 5.2 NA NA
13 NA NA NA NA
14 NA NA NA NA
The compounds were assayed in agonist mode using the DiscoverX cAMP and β-arrestin assays as described in the Materials and Methods. Data are expressed a percentage of the
maximum response to dopamine, which was assessed in each experiment. Data represent the means ± SEM from at least three separate experiments. NA, not active.
all agonist activity at the D2R. Overall, these data illustrate
the importance of a nitrogen at the ortho-position of ring D
(Figure 3B) in order for the compound to exert agonist activity
at the D2R and suggests that critical positioning occurs between
the ring D and D2R residues.
We were next interested in examining the effects of adding
a second nitrogen to ring D while maintaining the presence
of a nitrogen at the ortho-position. Introduction of a second
nitrogen at either the ortho- or meta-positions was well-tolerated
with pyrazine 18 (ortho-, meta-disubstitution) affording a G
protein-biased analog of comparable potency and efficacy to
MLS1547 (Table 2, Figure 8). The addition of a second nitrogen
at the ortho-position generally increased potency for G protein-
mediated signaling, but also led to efficacy for β-arrestin
recruitment (Table 2, 19, Figure 8, or Table 3, 39 and 42–46).
However, the addition of a second nitrogen to the ortho- or
meta-positions of ring D within analogs containing detrimental
modifications to the phenol moiety did not re-establish lost
agonist activity (Table 3, 33–36 and 40, 41, 47, and 48). Notably,
ortho-, para-disubstitution uniformly provided inactive analogs
(Table 2, 17 and Table 3, 31, and 32), again indicating the
sensitivity of the para-position of the D ring. Moreover, para
substitution of the pyrazine ring completed ablated agonist
activity (Table 2, 21 and 22), as previously observed for the 2-
pyridyl analog 20 (Table 2). Generally, we observed that, while
the addition of a second nitrogen at the meta-position increases
agonist potency, it results in a less biased compound. Adding a
second nitrogen meta to the linker results in somewhat scaffold-
dependent effects, whereas a second nitrogen para to the linker
causes a loss of agonist activity. These data support the need for
a single nitrogen ortho to the linker without any substitution at
the para-position to maintain the activity and bias of the parent
compound.
DISCUSSION
We previously identified MLS1547 as a G protein-biased agonist
at the D2R using a variety of signaling assays (Free et al.,
2014). G protein-mediated assays included D2R-stimulated
Ca2+ mobilization, via a chimeric Gqi5 protein, and D2R-
mediated inhibition of cAMP accumulation via Gi/o proteins;
β-arrestin recruitment assays included assessment of D2R-β-
arrestin interactions, as measured via BRET, and also the
DiscoverX β-galactosidase complementation assay (Free et al.,
2014). MLS1547 was characterized as exhibiting high efficacy
(relative to dopamine) in the G protein-mediated assays and
little efficacy in the β-arrestin recruitment assays (Free et al.,
2014). These assays, however, involved different cell types,
HEK293 and CHO (both non-neuronal), undoubtedly expressing
different types/levels of other proteins that could regulate
receptor coupling/function. Recently, it has been noted that the
determination of ligand signaling bias can depend on variables
such as cell background, receptor reserve, signal amplification
and even the kinetics of the assay (Kenakin and Christopoulos,
2013; Klein Herenbrink et al., 2016).
Notably, Chen et al. (2016) have replicated our results
showing that MLS1547 is a G protein-biased agonist using cAMP
inhibition assays and the DiscoverX β-arrestin recruitment assay.
Although, using two other β-arrestin recruitment assays, these
investigators found that MLS1547 exhibited some efficacy for
β-arrestin recruitment. One of these, the Tango assay, uses a
gene reporter amplification output and a 20 h incubation period
of test compounds with the cells. This assay output and time
format results in significant amplification of agonist responses
thus making estimation of relative efficacies difficult. The second
assay measured receptor-β-arrestin association via BRET, but
notably required transfection and over-expression of GRK2 in
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TABLE 2 | Modification and replacement of the 2-pyridyl moiety (R2).
Entry/cmpd
Structure (R2 =)
cAMP inhibition assay β-arrestin recruitment assay
EC50 (µM ± S.E.M.) Emax (% DA control ± S.E.M.) EC50 (µM ± S.E.M.) Emax (% DA control ± S.E.M.)
1 (MLS1547) 2.2 ± 0.6 95.4 ± 8.9 NA NA
15 NA NA NA NA
16 NA NA NA NA
17 NA NA NA NA
18 3.5 ± 3.4 83.8 ± 8.5 NA NA
19 0.7 ± 0.2 92.8 ± 2.1 0.5 ± 0.3 21.6 ± 5.7
20 NA NA NA NA
21 NA NA NA NA
22 NA NA NA NA
23 2.8 ± 1.2 66.8 ± 3.9 NA NA
24 NA NA NA NA
The compounds were assayed in agonist mode using the DiscoverX cAMP and β-arrestin assays as described in the Materials and Methods. Data are expressed a percentage of the
maximum response to dopamine, which was assessed in each experiment. Data represent the means ± SEM from at least three separate experiments. NA, not active.
order to detect a response. In contrast, using native levels of
GRKs, we found that MLS1547 was devoid of this activity
using a similar β-arrestin recruitment assay (Free et al., 2014).
Given these somewhat disparate results in measuring proximal
D2R-β-arrestin association, we were interested in investigating
a downstream pathway resulting from β-arrestin recruitment,
namely receptor internalization. We have previously shown,
using native brain tissue from wild-type and β-arrestin-2 knock-
out mice, that β-arrestin-2 is required for D2R internalization
(Skinbjerg et al., 2009).
Initially, we were interested in investigating MLS1547-
induced D2R internalization in HEK293 cells, a non-neuronal
cell type used for many of the β-arrestin recruitment assays
mentioned above. Two different approaches were utilized. Firstly,
we used a BRET assay that takes advantage of constitutive
bystander BRET between Rluc8 tagged D2R (donor) and a cell-
surface restricted GFP10 (lyn-GFP10, acceptor) (Namkung et al.,
2016). When the D2R is internalized in response to agonist, the
BRET signal is decreased due to the separation of the BRET
donor (D2R) and acceptor (lyn-GFP10) which remains at the
cell surface. In these assays, dopamine was shown to promote
robust internalization, however, MLS1547 was without effect.
In a second approach, we used a biotinylation assay to detect
D2Rs that had undergone internalization in response to agonist
treatment. In these assays, MLS1547 was found to promote
some detectable receptor internalization, but the efficacy of this
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TABLE 3 | Modification or replacement of both the hydroxyquinoline group (R1) and 2-pyridyl moiety (R2).
Entry/cmpd Structure (R1 =) cAMP inhibition assay β-arrestin recruitment assay
(R1 =) (R2 =) EC50 (µM ± S.E.M.) Emax (% DA control ± S.E.M.) EC50 (µM ± S.E.M.) Emax (% DA control ± S.E.M.)
1 (MLS1547) 2.2 ± 0.6 95.4 ± 8.9 NA NA
25 NA NA >39 NA
26 NA NA NA NA
27 NA NA NA NA
28 13.3 ± 8.6 70.0 ± 10.0 7.7 ± 0.3 34.9 ± 4.1
29 NA NA NA NA
30 NA NA NA NA
31 NA NA NA NA
32 NA NA NA NA
33 NA NA NA NA
34 NA NA NA NA
35 NA NA NA NA
36 NA NA NA NA
(Continued)
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TABLE 3 | Continued
Entry/cmpd Structure (R1 =) cAMP inhibition assay β-arrestin recruitment assay
(R1 =) (R2 =) EC50 (µM ± S.E.M.) Emax (% DA control ± S.E.M.) EC50 (µM ± S.E.M.) Emax (% DA control ± S.E.M.)
37 NA NA 24.8 ± 15.5 54.7 ± 5.1
38 27.3 ± 18.2 66.5 ± 20.6 NA NA
39 1.2 ± 0.4 59.3 ± 4.9 15.6 ± 8.8 53.4 ± 7.8
40 NA NA NA NA
41 NA NA NA NA
42 0.8 ± 0.4 58.7 ± 2.8 7.6 ± 1 46.5 ± 1.5
43 0.04 ± 0.01 58.2 ± 1.4 0.1 ± 0.01 75.1 ± 7.1
44 0.6 ± 0.5 44.4 ± 1.7 1.0 ± 0.2 61.4 ± 11.7
45 0.8 ± 0.1 51.6 ± 3.5 2.6 ± 1.1 70.6 ± 8.9
46 8.5 ± 4.0 90.1 ± 12.7 14.5 ± 1.5 85.6 ± 4.5
47 NA NA NA NA
48 NA NA NA NA
(Continued)
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TABLE 3 | Continued
Entry/cmpd Structure (R1 =) cAMP inhibition assay β-arrestin recruitment assay
(R1 =) (R2 =) EC50 (µM ± S.E.M.) Emax (% DA control ± S.E.M.) EC50 (µM ± S.E.M.) Emax (% DA control ± S.E.M.)
49 NA NA NA NA
50 NA NA NA NA
51 NA NA NA NA
The compounds were assayed in agonist mode using the DiscoverX cAMP and β-arrestin assays as described in the Materials and Methods. Data are expressed a percentage of the
maximum response to dopamine, which was assessed in each experiment. Data represent the means ± SEM from at least three separate experiments. NA, not active.
FIGURE 4 | A halogen moiety in area 1 on ring B of MLS1547 enables G protein-bias. CHO cells stably expressing the D2R were assayed for agonist-mediated
inhibition of forskolin-stimulated cAMP accumulation (A) or recruitment of β-arrestin to the D2R (B), as described in the Materials and Methods. Representative
experiments are shown with averaged curve parameters derived from at least three separate experiments displayed in Table 1. Data are expressed as a percentage
of the maximum response to dopamine, which was assessed in each experiment.
FIGURE 5 | A hydroxyl group in area 2 on ring B of MLS1547 is required for both potency and efficacy of G protein signaling. CHO cells stably expressing the D2R
were assayed for agonist-mediated inhibition of forskolin-stimulated cAMP accumulation (A) or recruitment of β-arrestin to the D2R (B), as described in the Materials
and Methods. Representative experiments are shown with averaged curve parameters derived from at least three separate experiments displayed in Table 1. Data are
expressed as a percentage of the maximum response to dopamine, which was assessed in each experiment.
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FIGURE 6 | Effects of combined modifications of areas 1 and 2 of ring B of MLS1547 on signaling bias. CHO cells stably expressing the D2R were assayed for
agonist-mediated inhibition of forskolin-stimulated cAMP accumulation (A) or recruitment of β-arrestin to the D2R (B), as described in the Materials and Methods.
Representative experiments are shown with averaged curve parameters derived from at least three separate experiments displayed in Table 1. Data are expressed as
a percentage of the maximum response to dopamine, which was assessed in each experiment.
FIGURE 7 | A hydrophobic moiety in the correct orientation is integral to G protein biased signaling activity of the MLS1547 scaffold. CHO cells stably expressing the
D2R were assayed for agonist-mediated inhibition of forskolin-stimulated cAMP accumulation (A) or recruitment of β-arrestin to the D2R (B), as described in the
Materials and Methods. Representative experiments are shown with averaged curve parameters derived from at least three separate experiments displayed in
Table 1. Data are expressed as a percentage of the maximum response to dopamine, which was assessed in each experiment.
FIGURE 8 | The addition of a second nitrogen at the 6-position of ring D increases agonist potency, but decreases G protein signaling bias. CHO cells stably
expressing the D2R were assayed for agonist-mediated inhibition of forskolin-stimulated cAMP accumulation (A) or recruitment of β-arrestin to the D2R (B), as
described in the Materials and Methods. Representative experiments are shown with averaged curve parameters derived from at least three separate experiments
displayed in Table 3. Data are expressed as a percentage of the maximum response to dopamine, which was assessed in each experiment.
response was quite low in comparison to that of a full, unbiased
D2R agonist. Our conclusion from these assays is that MLS1547
is nearly devoid of efficacy with respect to promoting D2R
internalization in HEK293 cells.
We were next interested in testing D2R internalization using
a more physiologically relevant model system and turned to
primary striatal neurons in culture. Two different approaches
were utilized. Firstly, we used immunocytochemistry techniques
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and an experimental design that can detect either the total cellular
receptor population (surface plus internalized) or just receptors
at the cell surface. Using this approach, dopamine treatment
was found to promote robust D2R internalization. MLS1547
treatment also promoted a low degree of statistically significant
internalization, however, the efficacy for this response was much
less than that for dopamine. We also used a completely different
approach to assess D2R internalization in the striatal neurons
that involved measuring reinsertion of internalized receptors at
the cell surface. This approach has previously been validated
by Li et al. (2012a,b) for assessing D2R internalization in
neuronal cultures. Using this technique, we found that dopamine
promoted extensive internalization of the D2R, whereas ML1547
treatment was without effect.
Our overall conclusion from these studies is that the
pharmacological properties of MLS1547 delineated in
heterologous expression systems were largely recapitulated
in native neuronal (striatal) tissue. While G protein-coupling
wasn’t examined directly, Scarduzio et al. (2017) recently showed
that MLS1547 decreases the firing rate of striatal neurons
through a D2R-activated Gi/o-mediated pathway indicating that
this compound does stimulate G protein-mediated signaling in
native striatal neurons. In contrast, Scarduzio et al. (2017) found
that the D2R β-arrestin-biased agonist, UNC9994 (Allen et al.,
2011; Chen et al., 2012) had no effect on striatal neuron firing
rate. (UNC9994 is actually an antagonist of D2R G protein-
mediated signaling). The biased signaling properties of UNC9994
may be similarly affected by the cellular milieu in which the
D2R is expressed. Urs et al. (2016, 2017) have suggested that
this D2R ligand exhibits greater efficacy for recruiting β-arrestin
in the cortex vs. the striatum, thus emphasizing the need to
evaluate functionally selective ligands within multiple cellular
contexts.
A second goal of the present study was to further investigate
the structural requirements for the biased signaling properties of
the MLS1547 scaffold. In general, we investigated modifications
of the scaffold within the four main areas shown in Figure 3.
Modifications of rings A and B, confirmed the need for a
hydrophobic moiety in the correct orientation to maintain G
protein-mediated signaling bias. This was exemplified through
modification (removal/substitution) of the halogen group on
the quinoline ring of MLS1547 or through substituting the
quinoline ring with other bicyclic aromatic moieties. Several
compounds were identified that exhibited a similar degree
of G protein-mediated signaling bias as MLS1547, however,
only one compound was found that exhibited greater (∼three-
fold) potency (12, Table 1) while still maintaining high bias.
Interestingly, within the quinoline series of compounds, we
identified a requirement for a hydroxyl group at the 8-position
(Area 2, Figure 3B) in order to maintain potency as well as G
protein-bias. These results suggest that the hydroxyl group forms
critical interactions with yet to be identified segments of the
D2R. This could be potentially exploited when formulating future
derivatives of MLS1547.
Our previous data also suggested an important role for the
pyridine moiety (Area 4, Figure 3B) of MLS1547 in terms of
conferring potency, likely through the formation of a hydrogen
bond to T412 of the D2R (Free et al., 2014). Cyclohexane
substitutions of this pyridine moiety led to a complete loss of
activity confirming the requirement for the aromaticity of this
ring. Interestingly, moving the nitrogen from the ortho-position
to either the meta- or para- positions lead to a decrease or loss
of agonist activity, indicating that the position of the nitrogen is
critical for D2R interactions. Notably, substitution at the para-
position of this ring leads to a complete loss of activity further
suggesting that critical positioning of this ring with D2R residues
occurs. Interestingly, the addition of a second nitrogen was well-
tolerated at the ortho- or meta- positions with meta substitution
increasing potency, but decreasing bias. Our conclusion is that a
nitrogen is required at the ortho-position of ring D for potent
agonist activity and G protein bias, the addition of a second
nitrogen at the meta-position can increase potency, but may
decrease bias, and the addition of a nitrogen at the para position
decreases all activity. It would be interesting to see if substitution
of the meta position of ring D with other groups might lead to an
enhancement of potency, yet maintain signaling bias.
Our results confirm and extend the pharmacophore model
that we proposed to explain the biased signaling activity of
MLS1547 (Free et al., 2014). In this model, docking of MLS1547
within the orthosteric binding site and a hydrophobic pocket near
the extracellular portion of TM5 affects the tilting of this receptor
region such that β-arrestin recruitment to the D2R is diminished.
Such a model has also been suggested to explain biased signaling
at the 5-HT2B serotonin receptor. Ergotamine is a β-arrestin-
biased agonist at the 5-HT2B serotonin receptor, but non-biased
at the 5-HT1B receptor. Wacker et al. (2013) crystalized both
receptors in the presence of ergotamine and found that, in the
5HT2B receptor structure, the extracellular portion of TM5 is
tilted toward the orthosteric binding site compared to the 5HT1B
receptor structure. Thus, agonists that prevent such a tilting of
TM5 might exhibit G protein signaling bias. As noted above,
other G protein-biased agonists have been described for the D2R
(Moller et al., 2014, 2017; Weichert et al., 2015; Chen et al., 2016;
Bonifazi et al., 2017), although the specific structural bases for
their biased activity were not proposed. It will thus be interesting
to see if there are structural commonalities for promoting G
protein-mediated biased signaling of the D2R or if multiple
mechanisms exist.
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